Molecular pathways: Current role and future directions of the retinoic acid pathway in cancer prevention and treatment

Roisin Connolly, Nguyen K. Nguyen, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

Retinoids and their naturally metabolized and synthetic products (e.g., all-trans retinoic acid, 13-cis retinoic acid, bexarotene) induce differentiation in various cell types. Retinoids exert their actions mainly through binding to the nuclear retinoic acid receptors (a , b, g ), which are transcriptional and homeostatic regulators with functions that are often compromised early in neoplastic transformation. The retinoids have been investigated extensively for their use in cancer prevention and treatment. Success has been achieved with their use in the treatment of subtypes of leukemia harboring chromosomal translocations. Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. Ongoing phase III randomized trials investigating retinoids in combination with chemotherapy in non-small cell lung cancer aim to definitively characterize the role of retinoids in this tumor type. The limited treatment success observed to date in the prevention and treatment of solid tumors may relate to the frequent epigenetic silencing of RARb. Robust evaluation of RARb and downstream genes may permit optimized use of retinoids in the solid tumor arena.

Original languageEnglish (US)
Pages (from-to)1651-1959
Number of pages309
JournalClinical Cancer Research
Volume19
Issue number7
DOIs
StatePublished - Apr 1 2013

Fingerprint

Retinoids
Tretinoin
Neoplasms
Therapeutics
Fenretinide
Breast Neoplasms
Isotretinoin
Genetic Translocation
Retinoic Acid Receptors
Combination Drug Therapy
Epigenomics
Non-Small Cell Lung Carcinoma
Direction compound
Leukemia
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular pathways : Current role and future directions of the retinoic acid pathway in cancer prevention and treatment. / Connolly, Roisin; Nguyen, Nguyen K.; Sukumar, Saraswati.

In: Clinical Cancer Research, Vol. 19, No. 7, 01.04.2013, p. 1651-1959.

Research output: Contribution to journalArticle

@article{7aa059bdd1c64ec2b4a04eb472837f83,
title = "Molecular pathways: Current role and future directions of the retinoic acid pathway in cancer prevention and treatment",
abstract = "Retinoids and their naturally metabolized and synthetic products (e.g., all-trans retinoic acid, 13-cis retinoic acid, bexarotene) induce differentiation in various cell types. Retinoids exert their actions mainly through binding to the nuclear retinoic acid receptors (a , b, g ), which are transcriptional and homeostatic regulators with functions that are often compromised early in neoplastic transformation. The retinoids have been investigated extensively for their use in cancer prevention and treatment. Success has been achieved with their use in the treatment of subtypes of leukemia harboring chromosomal translocations. Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. Ongoing phase III randomized trials investigating retinoids in combination with chemotherapy in non-small cell lung cancer aim to definitively characterize the role of retinoids in this tumor type. The limited treatment success observed to date in the prevention and treatment of solid tumors may relate to the frequent epigenetic silencing of RARb. Robust evaluation of RARb and downstream genes may permit optimized use of retinoids in the solid tumor arena.",
author = "Roisin Connolly and Nguyen, {Nguyen K.} and Saraswati Sukumar",
year = "2013",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-12-3175",
language = "English (US)",
volume = "19",
pages = "1651--1959",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Molecular pathways

T2 - Current role and future directions of the retinoic acid pathway in cancer prevention and treatment

AU - Connolly, Roisin

AU - Nguyen, Nguyen K.

AU - Sukumar, Saraswati

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Retinoids and their naturally metabolized and synthetic products (e.g., all-trans retinoic acid, 13-cis retinoic acid, bexarotene) induce differentiation in various cell types. Retinoids exert their actions mainly through binding to the nuclear retinoic acid receptors (a , b, g ), which are transcriptional and homeostatic regulators with functions that are often compromised early in neoplastic transformation. The retinoids have been investigated extensively for their use in cancer prevention and treatment. Success has been achieved with their use in the treatment of subtypes of leukemia harboring chromosomal translocations. Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. Ongoing phase III randomized trials investigating retinoids in combination with chemotherapy in non-small cell lung cancer aim to definitively characterize the role of retinoids in this tumor type. The limited treatment success observed to date in the prevention and treatment of solid tumors may relate to the frequent epigenetic silencing of RARb. Robust evaluation of RARb and downstream genes may permit optimized use of retinoids in the solid tumor arena.

AB - Retinoids and their naturally metabolized and synthetic products (e.g., all-trans retinoic acid, 13-cis retinoic acid, bexarotene) induce differentiation in various cell types. Retinoids exert their actions mainly through binding to the nuclear retinoic acid receptors (a , b, g ), which are transcriptional and homeostatic regulators with functions that are often compromised early in neoplastic transformation. The retinoids have been investigated extensively for their use in cancer prevention and treatment. Success has been achieved with their use in the treatment of subtypes of leukemia harboring chromosomal translocations. Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. Ongoing phase III randomized trials investigating retinoids in combination with chemotherapy in non-small cell lung cancer aim to definitively characterize the role of retinoids in this tumor type. The limited treatment success observed to date in the prevention and treatment of solid tumors may relate to the frequent epigenetic silencing of RARb. Robust evaluation of RARb and downstream genes may permit optimized use of retinoids in the solid tumor arena.

UR - http://www.scopus.com/inward/record.url?scp=84877091761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877091761&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-3175

DO - 10.1158/1078-0432.CCR-12-3175

M3 - Article

C2 - 23322901

AN - SCOPUS:84877091761

VL - 19

SP - 1651

EP - 1959

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -